Beatrice M. Razzo

Beatrice M. Razzo

Auto-generated profile, based on publicly available information

Beatrice M. Razzo

Division of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
BRBeatrice M. Razzo
Beatrice M. Razzo
SMShonali Midha
Shonali Midha
APAndrew Jay Portuguese
Andrew Jay Portuguese
AGAriel F. Grajales-Cruz
Ariel F. Grajales-Cruz
ACAndre De Menezes Silva Corraes
Andre De Menezes Silva Corraes
SRShambavi Richard
Shambavi Richard
Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for the MajesTEC-1 trial, primarily due to prior BCMA-directed therapy, cytopenias, or diminished performance status. Cytokine release syndrome occurred in 54% (1.4% grade ≥3) and immune effector cell–associated neurotoxicity syndrome in 11% (2.2% grade ≥3), with no fatal events. Infections occurred in 42% and contributed to death in 5%. Partial response (PR) or better was achieved in 53% and very good PR or better in 45%. With 10.1 months of median follow-up, the estimated median progression-free survival (PFS) was 5.8 months and 12-month overall survival was 61%. Independent predictors of less than very good PR and shorter PFS included BCMA-directed chimeric antigen receptor T-cell therapy in the previous 9 months, high disease burden, lymphopenia, and elevated ferritin. Significance: T cell–engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers. This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I/II study, and identifies clinical variables associated with treatment response. See related commentary by Zweegman et al., p. 542


3 November 2025
Verified
Other
Open access
PDF file
BRBeatrice M. Razzo
Beatrice M. Razzo
SMShonali Midha
Shonali Midha
APAndrew Jay Portuguese
Andrew Jay Portuguese
AGAriel F. Grajales-Cruz
Ariel F. Grajales-Cruz
ACAndre De Menezes Silva Corraes
Andre De Menezes Silva Corraes
SRShambavi Richard
Shambavi Richard
Supplemental Table 7: Univariable regression for overall response

3 November 2025
Verified
Other
Open access
BRBeatrice M. Razzo
Beatrice M. Razzo
SMShonali Midha
Shonali Midha
APAndrew Jay Portuguese
Andrew Jay Portuguese
AGAriel F. Grajales-Cruz
Ariel F. Grajales-Cruz
ACAndre De Menezes Silva Corraes
Andre De Menezes Silva Corraes
SRShambavi Richard
Shambavi Richard
Supplemental Table S5: Multiple myeloma responses

3 November 2025
Verified
Other
Open access
BRBeatrice M. Razzo
Beatrice M. Razzo
SMShonali Midha
Shonali Midha
APAndrew Jay Portuguese
Andrew Jay Portuguese
AGAriel F. Grajales-Cruz
Ariel F. Grajales-Cruz
ACAndre De Menezes Silva Corraes
Andre De Menezes Silva Corraes
SRShambavi Richard
Shambavi Richard
Supplemental Table S13: Progression-free survival univariable and multivariable regression analyses among patients with ≥VGPR

3 November 2025
Verified
Other
Open access
PDF file
BRBeatrice M. Razzo
Beatrice M. Razzo
SMShonali Midha
Shonali Midha
APAndrew Jay Portuguese
Andrew Jay Portuguese
AGAriel F. Grajales-Cruz
Ariel F. Grajales-Cruz
ACAndre De Menezes Silva Corraes
Andre De Menezes Silva Corraes
SRShambavi Richard
Shambavi Richard
Supplemental Table 2: Prior BCMA-directed therapy details